DDX53 and neoplasm: To evaluate whether CT26-mock tumor growth is dependent on NKG2D signaling, CT26-mock cells were subcutaneously implanted into syngeneic BALB/c mice and treated with either anti-NKG2D antibody or isotype control antibody (Figure 2B).